PMID- 35694260
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Comprehensive Evaluation of Anti-PD-1, Anti-PD-L1, Anti-CTLA-4 and Their Combined 
      Immunotherapy in Clinical Trials: A Systematic Review and Meta-analysis.
PG  - 883655
LID - 10.3389/fphar.2022.883655 [doi]
LID - 883655
AB  - Immunotherapy with immune checkpoint inhibitor (ICI) drugs is gradually becoming 
      a hot topic in cancer treatment. To comprehensively evaluate the safety and 
      efficacy of ICI drugs, we employed the Bayesian model and conducted a network 
      meta-analysis in terms of progression-free survival (PFS), overall survival (OS) 
      and severe adverse events (AEs). Our study found that treatment with ipilimumab 
      was significantly worse than standard therapies in terms of PFS, whereas 
      treatment with cemiplimab significantly improved PFS. The results also indicated 
      that cemiplimab was the best choice for PFS. Treatment with nivolumab, 
      pembrolizumab and nivolumab plus ipilimumab significantly improved OS compared to 
      standard therapies. In terms of OS, cemiplimab was found to be the best choice, 
      whereas avelumab was the worst. In terms of severe AEs, atezolizumab, avelumab, 
      durvalumab, nivolumab, and pembrolizumab all significantly reduced the risk of 
      grade 3 or higher AEs compared to standard therapy. The least likely to be 
      associated with severe AEs were as follows: cemiplimab, avelumab, nivolumab, 
      atezolizumab, and camrelizumab, with nivolumab plus ipilimumab to be the worst. 
      Therefore, different ICI drug therapies may pose different risks in terms of PFS, 
      OS and severe AEs. Our study may provide new insights and strategies for the 
      clinical practice of ICI drugs.
CI  - Copyright (c) 2022 Xiang, Li, Zhang, Cen, Chen, Jiang, Meng, Wang, Berglund, Zhai 
      and Wu.
FAU - Xiang, Ze
AU  - Xiang Z
AD  - Zhejiang University School of Medicine, Hangzhou, China.
FAU - Li, Jiayuan
AU  - Li J
AD  - Zhejiang University School of Medicine, Hangzhou, China.
FAU - Zhang, Zhengyu
AU  - Zhang Z
AD  - Center for Global Health, Department of Epidemiology, School of Public Health, 
      Nanjing Medical University, Nanjing, China.
FAU - Cen, Chao
AU  - Cen C
AD  - Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated 
      Hospital, Zhejiang University School of Medicine, Hangzhou, China.
FAU - Chen, Wei
AU  - Chen W
AD  - Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and 
      Western Medicine of Zhejiang Province, Tongde Hospital of Zhejiang Province, 
      Cancer Institute of Integrated Traditional Chinese and Western Medicine, Zhejiang 
      Academy of Traditional Chinese Medicine, Hangzhou, China.
FAU - Jiang, Bin
AU  - Jiang B
AD  - Department of Laboratory Medicine, The Central Blood Station of Yancheng City, 
      Yancheng, China.
FAU - Meng, Yiling
AU  - Meng Y
AD  - Department of Laboratory Medicine, Suzhou Vocational Health College, Suzhou, 
      China.
FAU - Wang, Ying
AU  - Wang Y
AD  - Department of Clinical Laboratory, Suzhou Municipal Hospital, Gusu School, The 
      Affiliated Suzhou Hospital of Nanjing Medical University, Nanjing Medical 
      University, Suzhou, China.
FAU - Berglund, Bjorn
AU  - Berglund B
AD  - Department of Biomedical and Clinical Sciences, Linkoping University, Linkoping, 
      Sweden.
FAU - Zhai, Guanghua
AU  - Zhai G
AD  - Department of Clinical Laboratory, Suzhou Municipal Hospital, Gusu School, The 
      Affiliated Suzhou Hospital of Nanjing Medical University, Nanjing Medical 
      University, Suzhou, China.
FAU - Wu, Jian
AU  - Wu J
AD  - Department of Clinical Laboratory, Suzhou Municipal Hospital, Gusu School, The 
      Affiliated Suzhou Hospital of Nanjing Medical University, Nanjing Medical 
      University, Suzhou, China.
LA  - eng
PT  - Systematic Review
DEP - 20220525
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC9174611
OTO - NOTNLM
OT  - cancer immunotherapy
OT  - cytotoxic T lymphocyte antigen-4 (CTLA-4)
OT  - immune checkpoint inhibitor
OT  - programmed death-1 (PD-1)
OT  - programmed death-ligand-1 (PD-L1)
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/14 06:00
MHDA- 2022/06/14 06:01
PMCR- 2022/05/25
CRDT- 2022/06/13 03:29
PHST- 2022/02/28 00:00 [received]
PHST- 2022/05/03 00:00 [accepted]
PHST- 2022/06/13 03:29 [entrez]
PHST- 2022/06/14 06:00 [pubmed]
PHST- 2022/06/14 06:01 [medline]
PHST- 2022/05/25 00:00 [pmc-release]
AID - 883655 [pii]
AID - 10.3389/fphar.2022.883655 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 May 25;13:883655. doi: 10.3389/fphar.2022.883655. 
      eCollection 2022.